Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

1.

IL-13 cytotoxin has potent antitumor activity and synergizes with paclitaxel in a mouse model of oral squamous cell carcinoma.

Kioi M, Shimamura T, Nakashima H, Hirota M, Tohnai I, Husain SR, Puri RK.

Int J Cancer. 2009 Mar 15;124(6):1440-8. doi: 10.1002/ijc.24067.

2.

Cancer gene therapy utilizing interleukin-13 receptor alpha2 chain.

Kawakami K.

Curr Gene Ther. 2005 Apr;5(2):213-23. Review.

PMID:
15853729
3.

Taxol: efficacy against oral squamous cell carcinoma.

Ledwitch K, Ogburn R, Cox J, Graham R, Fritzsche A, Gosnell D, Manning T.

Mini Rev Med Chem. 2013 Apr;13(4):509-21. Review.

PMID:
23373651
4.

Clinical studies with targeted toxins in malignant glioma.

Rainov NG, Söling A.

Rev Recent Clin Trials. 2006 May;1(2):119-31. Review.

PMID:
18473963
5.

Role of interleukin-13 in cancer, pulmonary fibrosis, and other T(H)2-type diseases.

Joshi BH, Hogaboam C, Dover P, Husain SR, Puri RK.

Vitam Horm. 2006;74:479-504. Review.

PMID:
17027527
6.

The IL-4 and IL-13 pseudomonas exotoxins: new hope for brain tumor therapy.

Shimamura T, Husain SR, Puri RK.

Neurosurg Focus. 2006 Apr 15;20(4):E11. Review.

PMID:
16709016
7.

Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy.

Kioi M, Husain SR, Croteau D, Kunwar S, Puri RK.

Technol Cancer Res Treat. 2006 Jun;5(3):239-50. Review.

PMID:
16700620
8.

Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside.

Husain SR, Puri RK.

J Neurooncol. 2003 Oct;65(1):37-48. Review.

PMID:
14649884
9.

Therapeutic targeting of IL-4- and IL-13-responsive cells in pulmonary fibrosis.

Jakubzick C, Kunkel SL, Puri RK, Hogaboam CM.

Immunol Res. 2004;30(3):339-49. Review.

PMID:
15531774

Supplemental Content

Support Center